Agree - I particularly liked the projected market growth on page 16 and the fact they have already completed a successful USD$20million credit raise in July 2020. Their work on the potential treatment of COVID19 using Bovine Colostrum as an oral therapeutic in the GI tract is also very exciting.
Page 16: CLOSTRIDIUM DIFFICILE MARKET OPPORTUNITY Clostridiodiodes difficile (C. difficile) is a bacterium that causes diarrhea and more serious intestinal conditions such as colitis
*Therapeutic market expected to grow from USD $630 million in 2016 to over $1.7 billion by 2026 CAGR 15% *Leading cause of gastroenteritis-associated mortality in U.S. *Approx. 44,500 patients died in 2014 from C. difficile infections (U.S.) *Potential orphan disease (7 years market exclusivity and premium pricing)
IMC Price at posting:
22.5¢ Sentiment: Buy Disclosure: Held
